These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 24442130

  • 1. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.
    Cirone P, Andresen CJ, Eswaraka JR, Lappin PB, Bagi CM.
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):525-38. PubMed ID: 24442130
    [Abstract] [Full Text] [Related]

  • 2. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
    Sheppard KE, Cullinane C, Hannan KM, Wall M, Chan J, Barber F, Foo J, Cameron D, Neilsen A, Ng P, Ellul J, Kleinschmidt M, Kinross KM, Bowtell DD, Christensen JG, Hicks RJ, Johnstone RW, McArthur GA, Hannan RD, Phillips WA, Pearson RB.
    Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
    [Abstract] [Full Text] [Related]

  • 3. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce ML, Carlson SG, Coupar JF, Zhang J, Cheng H, Chen Z, Van Waes C.
    Clin Cancer Res; 2015 Sep 01; 21(17):3946-56. PubMed ID: 25977343
    [Abstract] [Full Text] [Related]

  • 4. Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.
    Pitts TM, Newton TP, Bradshaw-Pierce EL, Addison R, Arcaroli JJ, Klauck PJ, Bagby SM, Hyatt SL, Purkey A, Tentler JJ, Tan AC, Messersmith WA, Eckhardt SG, Leong S.
    PLoS One; 2014 Sep 01; 9(11):e113037. PubMed ID: 25401499
    [Abstract] [Full Text] [Related]

  • 5. Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
    Simmons BH, Lee JH, Lalwani K, Giddabasappa A, Snider BA, Wong A, Lappin PB, Eswaraka J, Kan JL, Christensen JG, Shojaei F.
    Cancer Chemother Pharmacol; 2012 Aug 01; 70(2):213-20. PubMed ID: 22684718
    [Abstract] [Full Text] [Related]

  • 6. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 7. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
    Herzog A, Bian Y, Vander Broek R, Hall B, Coupar J, Cheng H, Sowers AL, Cook JD, Mitchell JB, Chen Z, Kulkarni AB, Van Waes C.
    Clin Cancer Res; 2013 Jul 15; 19(14):3808-19. PubMed ID: 23640975
    [Abstract] [Full Text] [Related]

  • 8. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
    Burmi RS, Maginn EN, Gabra H, Stronach EA, Wasan HS.
    Cancer Biol Ther; 2019 Jul 15; 20(1):21-30. PubMed ID: 30261145
    [Abstract] [Full Text] [Related]

  • 9. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.
    Bhattacharya B, Akram M, Balasubramanian I, Tam KK, Koh KX, Yee MQ, Soong R.
    Cancer Biol Ther; 2012 Jan 01; 13(1):34-42. PubMed ID: 22336586
    [Abstract] [Full Text] [Related]

  • 10. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ, Heo JH, Park JY, Jeong JY, Cho HJ, Park KS, Kim SH, Moon YW, Kim JS, An HJ.
    Gynecol Oncol; 2019 Apr 01; 153(1):135-148. PubMed ID: 30686552
    [Abstract] [Full Text] [Related]

  • 11. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F, El Botty R, Lavigne M, Gu C, Fuhrmann L, Briaux A, de Koning L, Dahmani A, Montaudon E, Morisset L, Huguet L, Sourd L, Painsec P, Chateau-Joubert S, Larcher T, Vacher S, Melaabi S, Salomon AV, Marangoni E, Bieche I.
    J Hematol Oncol; 2020 Feb 22; 13(1):13. PubMed ID: 32087759
    [Abstract] [Full Text] [Related]

  • 12. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK, Graab U, Fulda S.
    Cancer Lett; 2013 Sep 01; 337(2):200-9. PubMed ID: 23684925
    [Abstract] [Full Text] [Related]

  • 13. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
    Shukuya T, Yamada T, Koenig MJ, Xu J, Okimoto T, Li F, Amann JM, Carbone DP.
    J Thorac Oncol; 2019 Jun 01; 14(6):1061-1076. PubMed ID: 30825612
    [Abstract] [Full Text] [Related]

  • 14. Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.
    Zhao M, Scott S, Evans KW, Yuca E, Saridogan T, Zheng X, Wang H, Korkut A, Cruz Pico CX, Demirhan M, Kirby B, Kopetz S, Diala I, Lalani AS, Piha-Paul S, Meric-Bernstam F.
    Clin Cancer Res; 2021 Mar 15; 27(6):1681-1694. PubMed ID: 33414137
    [Abstract] [Full Text] [Related]

  • 15. Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells.
    Kim H, Lee SJ, Lee IK, Min SC, Sung HH, Jeong BC, Lee J, Park SH.
    Int J Mol Sci; 2020 Apr 18; 21(8):. PubMed ID: 32325639
    [Abstract] [Full Text] [Related]

  • 16. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S, Depreeuw J, Coenegrachts L, Hermans E, Lambrechts D, Amant F.
    Gynecol Oncol; 2015 Jul 18; 138(1):165-73. PubMed ID: 25933683
    [Abstract] [Full Text] [Related]

  • 17. Mutant HRAS as novel target for MEK and mTOR inhibitors.
    Kiessling MK, Curioni-Fontecedro A, Samaras P, Atrott K, Cosin-Roger J, Lang S, Scharl M, Rogler G.
    Oncotarget; 2015 Dec 08; 6(39):42183-96. PubMed ID: 26544513
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
    Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A.
    Clin Cancer Res; 2012 May 01; 18(9):2515-25. PubMed ID: 22392911
    [Abstract] [Full Text] [Related]

  • 19. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
    Haagensen EJ, Thomas HD, Mudd C, Tsonou E, Wiggins CM, Maxwell RJ, Moore JD, Newell DR.
    Eur J Cancer; 2016 Mar 01; 56():69-76. PubMed ID: 26820797
    [Abstract] [Full Text] [Related]

  • 20. Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.
    Wei BR, Michael HT, Halsey CH, Peer CJ, Adhikari A, Dwyer JE, Hoover SB, El Meskini R, Kozlov S, Weaver Ohler Z, Figg WD, Merlino G, Simpson RM.
    Pigment Cell Melanoma Res; 2016 Nov 01; 29(6):643-655. PubMed ID: 27463366
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.